Ischaemia–reperfusion (I–R) injury, initiated via bursts of reactive oxygen species produced
during the reoxygenation phase following hypoxia, is well known in a variety of acute …

Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and is frequently complicated by thrombosis. In some cases of …

The SARS‐CoV‐2 outbreak has been one of the largest public health crises globally, while
thrombotic complications have emerged as an important factor contributing to mortality …

Background Resistance to fibrinolysis, levels of procoagulant/antifibrinolytic neutrophil
extracellular traps (NETs), and the severity of acute ischemic stroke (AIS) are increased by …

Abstract United States Food and Drug Administration (FDA)‐approved viscoelastic testing
(VET) methodologies have significantly changed in the last 10 years, with the availability of …

Background Thrombogenicity is a known complication of COVID‐19, resulting from SARS‐
CoV‐2 infection, with significant effects on morbidity and mortality. Objective We aimed to …

Coagulopathy alongside micro-and macrovascular thrombotic events were frequent
characteristics of patients presenting with acute COVID-19 during the initial stages of the …

COVID-19 is a multisystem disease caused by SARS-CoV-2 and is associated with an
imbalance between the coagulation and fibrinolytic systems. Overall, hypercoagulation …

An impaired fibrinolytic process has been demonstrated in patients infected with SARS-CoV-
2, including those in severe or critical condition. Disruption of fibrinolysis leads to fibrin …

Acute extensive portal venous system thrombosis (PVST) can cause lethal complications.
Herein, we have for the first time reported the use of anticoagulation combined with systemic …